Author Correction: Vaccination induces broadly neutralizing antibody precursors to HIV gp41

Affiliations

• ¹ Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.
• ² IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA, USA.
• ³ Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery (CHAVD), The Scripps Research Institute, La Jolla, CA, USA.
• ⁴ Institute for Drug Discovery, Leipzig University Medical Faculty, Leipzig, Germany.
• ⁵ Division of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, CA, USA.
• ⁶ The Ragon Institute of Mass General, MIT and Harvard, Cambridge, MA, USA.
• ⁷ Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, USA.
• ⁸ Howard Hughes Medical Institute, Program in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, MA, USA.
• ⁹ Department of Genetics, Harvard Medical School, Boston, MA, USA.
• ¹⁰ School of Biological Sciences, University of Southampton, Southampton, UK.
• ¹¹ Department of Molecular Medicine, The Scripps Research Institute, La Jolla, CA, USA.
• ¹² Department of Biochemistry and Molecular Genetics, University of Louisville School of Medicine, Louisville, KY, USA.
• ¹³ Moderna, Inc., Cambridge, MA, USA.
• ¹⁴ Department of Computer Science, Dartmouth College, Hanover, NH, USA.
• ¹⁵ Division of Microbiology and Immunology, Emory National Primate Research Center, Emory University, Atlanta, GA, USA.
• ¹⁶ Department of Microbiology and Immunology, Emory School of Medicine, Atlanta, GA, USA.
• ¹⁷ Multi-omics Vaccine Evaluation Consortium, The Scripps Research Institute, La Jolla, CA, USA.
• ¹⁸ San Diego Center for AIDS Research, The Scripps Research Institute, La Jolla, CA, USA.
• ¹⁹ Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, USA.
• ²⁰ Department of Biological Sciences, Dartmouth College, Hanover, NH, USA.
• ²¹ Generate Biomedicines, Inc., Somerville, MA, USA.
• ²² IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA, USA. wilson@scripps.edu.
• ²³ Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery (CHAVD), The Scripps Research Institute, La Jolla, CA, USA. wilson@scripps.edu.
• ²⁴ Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, USA. wilson@scripps.edu.
• ²⁵ The Ragon Institute of Mass General, MIT and Harvard, Cambridge, MA, USA. fbatista1@mgh.harvard.edu.
• ²⁶ Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA. fbatista1@mgh.harvard.edu.
• ²⁷ Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery (CHAVD), The Scripps Research Institute, La Jolla, CA, USA. shane@lji.org.
• ²⁸ Division of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, CA, USA. shane@lji.org.
• ²⁹ Division of Infectious Diseases, Department of Medicine, University of California San Diego, La Jolla, CA, USA. shane@lji.org.
• ³⁰ Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA. schief@scripps.edu.
• ³¹ IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA, USA. schief@scripps.edu.
• ³² Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery (CHAVD), The Scripps Research Institute, La Jolla, CA, USA. schief@scripps.edu.
• ³³ The Ragon Institute of Mass General, MIT and Harvard, Cambridge, MA, USA. schief@scripps.edu.
• ³⁴ Moderna, Inc., Cambridge, MA, USA. schief@scripps.edu.